NPC
AST

National Planning Corporation’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

National Planning Corporation’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-115
Closed -$412 – 2747
2014
Q4 		$412 Buy
+115
New +$463 ﹤0.01% 2794

Other funds holding AST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
AIM
Allen Investment Management New York $8.09B AUM 16.78% 1-Year Est. Return

National Planning Corporation's AST Position: Q1 2015 in Review

National Planning Corporation sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2015, closing a stake of 115 shares — an estimated $412 sold.

National Planning Corporation first reported a position in AST in Q4 2014 and held it in 1 quarter. The position peaked at $412 in Q4 2014. 39 funds tracked by Wall St. Rank hold AST as of Q1 2015.

  • National Planning Corporation reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2015 after selling out during the quarter.
  • National Planning Corporation sold 115 Asterias Biotherapeutics Inc. Series A shares in Q1 2015, an estimated $412.
  • National Planning Corporation first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 1 quarter.
  • National Planning Corporation's Asterias Biotherapeutics Inc. Series A position peaked at $412 in Q4 2014.
  • 39 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2015.

Based on National Planning Corporation's 13F filing for Q1 2015, filed 12 May 2015.